© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#NASH
Companies Announce More NASH Drug Disappointments
The Liver Disease That Threatens Us All
NASH 101

What’s the Difference between NAFL, NAFLD and NASH?

A look at 3 forms of fatty liver disease: Non-Alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis

Testing People With Diabetes Can Detect More Liver Disease

Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.

What are the complications of fatty liver disease?

Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.

International Registries Shed More Light on Liver Disease and COVID-19

People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.

Multidisciplinary NAFLD Approach Improves Cardiovascular Risk

Researchers reported significant changes in liver, cardiovascular and diabetes markers.

NAFLD Screening of People With Type 2 Diabetes Is Cost-Effective

Researchers recommend screening for fatty liver disease within this population.

MUST read

Red Cooler "Human Organ for Transplant"
Fatty Liver Disease–Related Transplants on the Rise Among Young Adults
What Is Fatty Liver Disease And Is It Serious?
liver illustration
Is NASH the Next Hepatitis C?

Fatty Liver Disease Tied to Metabolic Health Conditions in People With HIV

As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.

Nonobese People Account for 40% of Global NAFLD Population

A fifth of the worldwide population with fatty liver disease consists of lean people.

NASH Is the Second Leading Indication for Liver Transplants

The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.

Egrifta Improves Liver Health in People With HIV

The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.

Company Halts Leading NASH Drug but Another Shows Promise

Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.

Hot topics

illustration of colorful pills with smile and frown faces
NAFLD/NASH Medication Drug Chart
What are the symptoms of NAFLD/NASH?

Diabetes More Than Doubles Risk of Advanced Liver Disease

Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.

FDA Delays Approval of Ocaliva for Fatty Liver Disease

The regulatory agency requested further data to show whether its benefits outweigh its risks.

Fatty Liver Disease Is Less Common but More Severe in Women

While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.

Fatty Liver Disease Tied to Reduced Capacity for Exertion in Adolescents

This connection may be attributable to lower iron levels.

Even Lean People With HIV Can Get Fatty Liver Disease

Nearly a quarter of lean HIV-positive people in a recent study had NAFLD, and 16% of them developed fibrosis.
Advertisement
Treatment News
Features